itolizumab inn trade name alzumab first class humanized monoclonal antibody developed center molecular immunology cim selectively targets pan cell marker involved costimulation adhesion maturation cells itolizumab binding regulates cell activation causes reduction synthesis proinflammatory cytokines possibly plays important role reducing cell infiltration sites double blind placebo controlled phase iii treat study itolizumab successfully met prespecified primary endpoint significant improvement psoriasis area severity index score weeks treatment patients moderate severe psoriasis compared biocon received marketing authorization drug drugs controller general india dcgi january marketing within india commenced august july biocon received authorization india use treatment immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikiitolizumab